165 related articles for article (PubMed ID: 24982452)
1. Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?
Jain P; Ok CY; Konoplev S; Patel KP; Jorgensen J; Estrov Z; Luthra R; Kantarjian H; Ravandi F
J Clin Oncol; 2016 Mar; 34(7):e57-60. PubMed ID: 24982452
[No Abstract] [Full Text] [Related]
2. A
Gozzetti A; Sammartano V; Bacchiarri F; Raspadori D; Bocchia M
Turk J Haematol; 2020 Nov; 37(4):286-287. PubMed ID: 32539314
[No Abstract] [Full Text] [Related]
3. How I manage patients with hairy cell leukaemia.
Thompson PA; Ravandi F
Br J Haematol; 2017 May; 177(4):543-556. PubMed ID: 28146266
[TBL] [Abstract][Full Text] [Related]
4. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
Dietrich S; Hüllein J; Hundemer M; Lehners N; Jethwa A; Capper D; Acker T; Garvalov BK; Andrulis M; Blume C; Schulte C; Mandel T; Meissner J; Fröhling S; von Kalle C; Glimm H; Ho AD; Zenz T
J Clin Oncol; 2013 Jul; 31(19):e300-3. PubMed ID: 23690412
[No Abstract] [Full Text] [Related]
5. Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia.
Forconi F; Toraldo F; Sozzi E; Amato T; Raspadori D; Lauria F
Leuk Lymphoma; 2007 Dec; 48(12):2441-3. PubMed ID: 18067021
[No Abstract] [Full Text] [Related]
6. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
Xi L; Arons E; Navarro W; Calvo KR; Stetler-Stevenson M; Raffeld M; Kreitman RJ
Blood; 2012 Apr; 119(14):3330-2. PubMed ID: 22210875
[TBL] [Abstract][Full Text] [Related]
7. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
8. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Wierda WG; Byrd JC; Abramson JS; Bhat S; Bociek G; Brander D; Brown J; Chanan-Khan A; Coutre SE; Davis RS; Fletcher CD; Hill B; Kahl BS; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Lancet J; Ma S; Malek S; Mosse C; Shadman M; Siddiqi T; Stephens D; Wagner N; Zelenetz AD; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2017 Nov; 15(11):1414-1427. PubMed ID: 29118233
[TBL] [Abstract][Full Text] [Related]
9. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant.
Imamura T; Ohtsuka E; Ogata M; Oka F; Kashima K; Kikuchi H; Nasu M
Int J Hematol; 2004 Dec; 80(5):432-4. PubMed ID: 15646655
[TBL] [Abstract][Full Text] [Related]
10. Discrepant results for BRAF V600E mutation among different specimens in a case of hairy cell leukemia.
Moon HW; Hur M; Han SH; Yun YM; Kim SY
Ann Lab Med; 2013 Jul; 33(4):300-3. PubMed ID: 23826570
[No Abstract] [Full Text] [Related]
11. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Kreitman RJ; Wilson W; Calvo KR; Arons E; Roth L; Sapolsky J; Zhou H; Raffeld M; Stetler-Stevenson M
Clin Cancer Res; 2013 Dec; 19(24):6873-81. PubMed ID: 24277451
[TBL] [Abstract][Full Text] [Related]
12. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
13. [Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?].
Troussard X; Maitre E; Paillassa J
Bull Cancer; 2021; 108(7-8):771-778. PubMed ID: 34023063
[TBL] [Abstract][Full Text] [Related]
14. Hairy-cell leukaemia: first-line treatment with cladribine or pentostatin.
Prescrire Int; 2006 Aug; 15(84):143-4. PubMed ID: 16989031
[TBL] [Abstract][Full Text] [Related]
15. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
[TBL] [Abstract][Full Text] [Related]
16. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.
Cornet E; Delmer A; Feugier P; Garnache-Ottou F; Ghez D; Leblond V; Levy V; Maloisel F; Re D; Zini JM; Troussard X;
Ann Hematol; 2014 Dec; 93(12):1977-83. PubMed ID: 24994538
[TBL] [Abstract][Full Text] [Related]
17. Hairy cell leukemia: Past, present and future.
Getta BM; Park JH; Tallman MS
Best Pract Res Clin Haematol; 2015 Dec; 28(4):269-72. PubMed ID: 26614906
[TBL] [Abstract][Full Text] [Related]
18. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J; Maitre E; Troussard X
Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
[TBL] [Abstract][Full Text] [Related]
19. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
[TBL] [Abstract][Full Text] [Related]
20. My treatment approach to hairy cell leukemia.
Naik RR; Saven A
Mayo Clin Proc; 2012 Jan; 87(1):67-76. PubMed ID: 22212971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
